0A9G fundamentals
An in-depth look to MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS operating, investing, and financing activities
0A9G free cash flow for Q1 24 is -7.99 M USD. For 2023, 0A9G free cash flow was -21.21 M USD and operating cash flow was -21.21 M USD.
Q1 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
Q1 '24
TTM